<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00555997</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-000623</org_study_id>
    <nct_id>NCT00555997</nct_id>
    <nct_alias>NCT00657592</nct_alias>
  </id_info>
  <brief_title>A 12-Week, Placebo Controlled Trial of Ziprasidone as Monotherapy for Major Depressive Disorder</brief_title>
  <acronym>Geodon</acronym>
  <official_title>A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge Health Alliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Connecticut</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Psychiatric Medicine Associates, L.L.C.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study on the effectiveness, tolerability and safety of oral ziprasidone as
      monotherapy in patients with major depressive disorder (MDD). Outpatients suffering from MDD
      will be treated with either ziprasidone or placebo for 12 weeks.

      Hypothesis: There will be a statistically significant difference in the magnitude of
      response, as measured by a decrease in baseline 17-item Hamilton Depression Rating Scale
      (HAM-D-17) scores, between the two treatment groups; the reduction in HAM-D-17 scores will be
      greater in the ziprasidone monotherapy group than in the placebo group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exploratory hypothesis 1: There will be a statistically significant difference in the
      percentage of responders in the two treatment groups; response rates will be significantly
      higher for the ziprasidone monotherapy compared to the placebo group.

      Exploratory hypothesis 2: The change in 6-VAS-D scores during the trial will be highly
      correlated to the change in HAM-D-17 and QIDS-SR during the trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D-17) Scores</measure>
    <time_frame>6 weeks</time_frame>
    <description>Higher numbers represent more symptoms of a major depressive episode. Minimum is 0. Maximum is 52.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder/Non-responder</measure>
    <time_frame>6 weeks</time_frame>
    <description>A responder during phase 1 or phase 2 is someone who demonstrated a 50% or greater decrease in HAMD-17 scores during phase 1 or phase 2 (corresponding).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 6-VAS-D Scores During Each Phase.</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in group 1 will receive Ziprasidone for the full 12 weeks of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in Group 2 will receive placebo for the first 6 weeks of the study, then will receive Ziprasidone for the last 6 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in Group 3 will receive placebo for the full 12 weeks of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Geodon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0mg Placebo per day. &quot;Dose increases&quot; and &quot;dose decreases&quot; may occur, but patient will remain at 0mg placebo</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-65.

          2. Written informed consent.

          3. MDD, current according to the fourth version of the Diagnostic and Statistical Manual
             for Mental Disorders (DSM-IV) as diagnosed by the Mini International Neuropsychiatric
             Interview (MINI; Sheehan et al, 1998).

          4. Quick Inventory of Depressive Symptomatology - Self-Rated (QIDS-SR- Trivedi et al,
             2004) score of at least 10 at both screen and baseline visits.

        Exclusion Criteria:

          1. Pregnant women.

          2. Women of child bearing potential who are not using a medically accepted means of
             contraception (to include oral contraceptive or implant, condom, diaphragm,
             spermicide, intrauterine device, tubal ligation, or a partner with vasectomy).

          3. Treatment with antidepressants for 2 weeks prior to the screen visit. If interested in
             discontinuing their current medication, potential participants must discuss this
             possibility with the prescribing physician. Study doctors will not implement any form
             of treatment washout.

          4. Patients who no longer meet DSM-IV criteria for MDD during the baseline visit, or
             patients who demonstrate a 25% or greater reduction in QIDS-SR scores, screening to
             baseline.

          5. Serious suicide or homicide risk, as assessed by the evaluating clinician or a score
             of 4 on the third item of the HAM-D.

          6. Unstable medical illness including cardiovascular, hepatic, renal, respiratory,
             endocrine, neurological, or hematological disease.

          7. Patients who meet criteria for alcohol or substance dependence, active within the last
             month.

          8. Any bipolar disorder (current or past).

          9. Any psychotic disorder (current or past).

         10. Psychotic features in the current episode or a history of psychotic features.

         11. History of a seizure disorder.

         12. Clinical or laboratory evidence of untreated hypothyroidism.

         13. Patients requiring excluded medications (see table 1 for details).

         14. Prior course of ziprasidone, or intolerance to ziprasidone at any dose.

         15. Any investigational psychotropic drug within the last 3 months.

         16. Patients with significant cardiac conduction problems on screening electrocardiogram
             such as atrial fibrillation, atrial flutter, atrio-ventricular block, prolonged or
             abnormal QTc interval (i.e. QTc&gt;450msec), or prolonged QRS interval.

         17. Patients who have suffered a myocardial infarction within the past 12 months, with
             uncompensated heart failure, or a history of QTc prolongation.

         18. Patients with abnormal serum potassium or magnesium levels upon screening.

         19. Patients currently taking other drugs that prolong the QTc including dofetilide,
             sotalol, quinidine, class Ia antiarrhythmics, class III antiarrhythmics, mesoridazine,
             thioridazine, chlorpromazine, droperidol, pimozide, sparfloxacin, gatifloxacin,
             moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl
             acetate, dolasetron methylate, probucol or tacrolimus.

         20. Patients who have failed to experience significant clinical improvement following 3 or
             more antidepressant trials of adequate duration (at least 6 weeks) and dose (minimal
             effective doses defined as: fluoxetine, paroxetine, citalopram 20mg; sertraline,
             fluvoxamine 50mg, escitalopram 10mg, paroxetine CR 25mg, venlafaxine 75mg, duloxetine
             60mg, bupropion 150mg, 15mg of mirtazapine, trazodone or nefazodone 300mg).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George I Papakostas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John M Zajecka, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Psychiatric Medicine Associates, L.L.C.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard C Shelton, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Winokur, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UConn Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gustavo Kinrys, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cambridge Health Alliance</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Waguih IsHak, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedar's Sinai</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mahmoud S Okasha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Comprehensive Psychiatric Care, Norwich CT</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030-6415</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Psychiatric Care</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatric Medicine Associates, L.L.C.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hosptial</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge Health Alliance</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.massgeneral.org/allpsych/depression/</url>
    <description>Depression Clinical and Research Program at MGH</description>
  </link>
  <results_reference>
    <citation>Papakostas GI, Vitolo OV, Ishak WW, Rapaport MH, Zajecka JM, Kinrys G, Mischoulon D, Lipkin SH, Hails KA, Abrams J, Ward SG, Meisner A, Schoenfeld DA, Shelton RC, Winokur A, Okasha MS, Bari MA, Fava M. A 12-week, randomized, double-blind, placebo-controlled, sequential parallel comparison trial of ziprasidone as monotherapy for major depressive disorder. J Clin Psychiatry. 2012 Dec;73(12):1541-7. doi: 10.4088/JCP.12m07670.</citation>
    <PMID>23290327</PMID>
  </results_reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2007</study_first_submitted>
  <study_first_submitted_qc>November 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2007</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>June 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2014</results_first_posted>
  <last_update_submitted>June 23, 2014</last_update_submitted>
  <last_update_submitted_qc>June 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>George I. Papakostas</investigator_full_name>
    <investigator_title>Director of Treatment-Resistant Studies, Depression Clinical and Research Program</investigator_title>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Major Depression</keyword>
  <keyword>Depression</keyword>
  <keyword>Geodon</keyword>
  <keyword>Ziprasidone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Phase 1 Ziprasidone</title>
          <description>Subjects taking ziprasidone in the first phase.</description>
        </group>
        <group group_id="P2">
          <title>Phase 1 Placebo</title>
          <description>Subjects taking placebo in the first phase.</description>
        </group>
        <group group_id="P3">
          <title>Phase 2 Ziprasidone</title>
          <description>Subjects taking ziprasidone in the second phase.</description>
        </group>
        <group group_id="P4">
          <title>Phase 2 Placebo</title>
          <description>Patients who received placebo in phase 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase 1 SPCD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="91"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="76"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Phase 2 SPCD</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo/Ziprasidone</title>
          <description>Received placebo in first phase and ziprasidone in second phase</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects received placebo throughout study</description>
        </group>
        <group group_id="B3">
          <title>Ziprasidone</title>
          <description>Subjects received ziprasidone throughout study</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="47"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.1" spread="11.1"/>
                    <measurement group_id="B2" value="44.6" spread="11.0"/>
                    <measurement group_id="B3" value="41.5" spread="10.6"/>
                    <measurement group_id="B4" value="43.7" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale (HAM-D-17) Scores</title>
        <description>Higher numbers represent more symptoms of a major depressive episode. Minimum is 0. Maximum is 52.</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone Phase I</title>
            <description>Results from phase I for those taking ziprasidone during that phase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Phase I</title>
            <description>Results from phase I for those taking placebo during that phase</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone Phase II</title>
            <description>Results from phase II for those taking ziprasidone during that phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II</title>
            <description>Results from phase II for those taking placebo during that phase</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale (HAM-D-17) Scores</title>
          <description>Higher numbers represent more symptoms of a major depressive episode. Minimum is 0. Maximum is 52.</description>
          <units>points</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mean phase baseline score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1" spread="5.5"/>
                    <measurement group_id="O2" value="19.9" spread="4.8"/>
                    <measurement group_id="O3" value="14.7" spread="3.9"/>
                    <measurement group_id="O4" value="15.6" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean phase score reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" spread="7.3"/>
                    <measurement group_id="O2" value="-7.1" spread="7.0"/>
                    <measurement group_id="O3" value="-2.1" spread="5.2"/>
                    <measurement group_id="O4" value="-4.3" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder/Non-responder</title>
        <description>A responder during phase 1 or phase 2 is someone who demonstrated a 50% or greater decrease in HAMD-17 scores during phase 1 or phase 2 (corresponding).</description>
        <time_frame>6 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone Phase I</title>
            <description>Results from phase I for those taking ziprasidone during that phase</description>
          </group>
          <group group_id="O2">
            <title>Placebo Phase I</title>
            <description>Results from phase I for those taking placebo during that phase</description>
          </group>
          <group group_id="O3">
            <title>Ziprasidone Phase II</title>
            <description>Results from phase II for those taking ziprasidone during that phase</description>
          </group>
          <group group_id="O4">
            <title>Placebo Phase II</title>
            <description>Results from phase II for those taking placebo during that phase</description>
          </group>
        </group_list>
        <measure>
          <title>Responder/Non-responder</title>
          <description>A responder during phase 1 or phase 2 is someone who demonstrated a 50% or greater decrease in HAMD-17 scores during phase 1 or phase 2 (corresponding).</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.8"/>
                    <measurement group_id="O2" value="31.8"/>
                    <measurement group_id="O3" value="23.8"/>
                    <measurement group_id="O4" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in 6-VAS-D Scores During Each Phase.</title>
        <time_frame>6 weeks</time_frame>
        <population>Forms not analyzable due to insufficient standardization across sites.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1 Ziprasidone</title>
            <description>Subjects taking ziprasidone in the first phase.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Placebo</title>
            <description>Subjects taking placebo in the first phase.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 Ziprasidone</title>
            <description>Subjects taking ziprasidone in the second phase.</description>
          </group>
          <group group_id="O4">
            <title>Phase 2 Placebo</title>
            <description>Patients who received placebo in phase 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6-VAS-D Scores During Each Phase.</title>
          <population>Forms not analyzable due to insufficient standardization across sites.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ziprasidone</title>
          <description>Adverse events experienced by subjects while taking ziprasidone</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Adverse events experienced when taking placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization due to suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1.0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Blurry/Double Vision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation/Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Akathisia/Agitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. George Papakostas</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-6697</phone>
      <email>gpapakostas@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

